Trial Profile
Retrospective cohort study of daclizumab in patients with multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jul 2020
Price :
$35
*
At a glance
- Drugs Daclizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 29 Oct 2018 New trial record
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis